Nkarta Reaches FDA Agreement on Ntrust Trial Changes

Nkarta, Inc. announced an agreement with the FDA on key changes to its Ntrust-1 and Ntrust-2 clinical trials for NKX019, an investigational CAR-NK cell therapy for autoimmune diseases. The amendments will enable outpatient administration, significantly reducing patient burden by cutting monitoring time from 24 hours to 2 hours, and expanding access to community research centers. Additionally, the company gained flexibility to re-dose patients in both studies and will add a rheumatoid arthritis cohort to Ntrust-2, broadening the trial's scope.